Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Cahn

Showing results (11-20 of 207) with videos related to

Pageof 21
Sort By:
The Journal of Antimicrobial Chemotherapy|December 17, 2009
Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabinePedro Cahn, Mark A Wainberg
The Lancet. HIV|September 25, 2018
Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1Juan P Jaworski, Pedro Cahn
Acta Gastroenterologica Latinoamericana|July 26, 2006
[Current treatment of HIV infection ]Pedro Cahn, Guillermo Benchetrit, Héctor Laplumé
Current Opinion in HIV and AIDS|May 18, 2018
Fostemsavir: a new CD4 attachment inhibitorPedro Cahn, Valeria Fink, Patricia Patterson
Advanced Drug Delivery Reviews|April 28, 2016
Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategiesOmar Sued, María Inés Figueroa, Pedro Cahn
Medicina|December 22, 2019
Novel preventive and therapeutic strategies against HIV infectionJuan Pablo Jaworski, Claudia Frola, Pedro Cahn
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|October 15, 2003
Tuberculosis and HIV: a partnership against the most vulnerablePedro Cahn, Hector Perez, Graciela Ben, et al.
Current Opinion in HIV and AIDS|April 18, 2009
The role of HIV research in building health system capacity in developing countriesDebrework Zewdie, Pedro Cahn, Craig McClure, et al.
Expert Opinion on Investigational Drugs|February 25, 2012
Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDSFatih M Uckun, Pedro Cahn, Sanjive Qazi, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 28, 2014
[Lopinavir/ritonavir in new initial antiretroviral treatment strategies]María José Rolón, María Inés Figueroa, Omar Sued, et al.
Pageof 21

Showing results (11-20 of 207) with videos related to

Sort By:
Pageof 21
The Journal of Antimicrobial Chemotherapy|December 17, 2009
Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabinePedro Cahn, Mark A Wainberg
The Lancet. HIV|September 25, 2018
Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1Juan P Jaworski, Pedro Cahn
Acta Gastroenterologica Latinoamericana|July 26, 2006
[Current treatment of HIV infection ]Pedro Cahn, Guillermo Benchetrit, Héctor Laplumé
Current Opinion in HIV and AIDS|May 18, 2018
Fostemsavir: a new CD4 attachment inhibitorPedro Cahn, Valeria Fink, Patricia Patterson
Advanced Drug Delivery Reviews|April 28, 2016
Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategiesOmar Sued, María Inés Figueroa, Pedro Cahn
Medicina|December 22, 2019
Novel preventive and therapeutic strategies against HIV infectionJuan Pablo Jaworski, Claudia Frola, Pedro Cahn
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|October 15, 2003
Tuberculosis and HIV: a partnership against the most vulnerablePedro Cahn, Hector Perez, Graciela Ben, et al.
Current Opinion in HIV and AIDS|April 18, 2009
The role of HIV research in building health system capacity in developing countriesDebrework Zewdie, Pedro Cahn, Craig McClure, et al.
Expert Opinion on Investigational Drugs|February 25, 2012
Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDSFatih M Uckun, Pedro Cahn, Sanjive Qazi, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 28, 2014
[Lopinavir/ritonavir in new initial antiretroviral treatment strategies]María José Rolón, María Inés Figueroa, Omar Sued, et al.
Pageof 21